e-learning
resources
Virtual 2020
Pre-Congress Content
News on diagnosis and therapy of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA)
I. Strambu (Bucharest, Romania), L. Fagard (Mechelen, Belgium), P. Ford (Mechelen, Belgium), T. Van Der Aa (Mechelen, Belgium), A. De Haas-Amatsaleh (Mechelen, Belgium), E. Santermans (Mechelen, Belgium), C. Seemayer (Mechelen, Belgium)
Source:
Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Session:
News on diagnosis and therapy of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
784
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Strambu (Bucharest, Romania), L. Fagard (Mechelen, Belgium), P. Ford (Mechelen, Belgium), T. Van Der Aa (Mechelen, Belgium), A. De Haas-Amatsaleh (Mechelen, Belgium), E. Santermans (Mechelen, Belgium), C. Seemayer (Mechelen, Belgium). Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA). 784
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA)
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021
Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018
Year: 2018
Phase 2B dose selection of BG00011 for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study
Source: Eur Respir J 2006; 28: Suppl. 50, 383s
Year: 2006
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018
Year: 2019
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Source: Eur Respir J 2016; 47: 243-253
Year: 2016
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept